Marc F Botteman
Overview
Explore the profile of Marc F Botteman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Postma M, Noone D, Rozenbaum M, Carter J, Botteman M, Fenwick E, et al.
Orphanet J Rare Dis
. 2022 Apr;
17(1):157.
PMID: 35382853
Conventional cost-effectiveness analysis-i.e., assessing pharmaceuticals through a cost per quality-adjusted life year (QALY) framework-originated from a societal commitment to maximize population health given limited resources. This "extra-welfarist" approach has produced...
2.
Liu R, Oluwole O, Diakite I, Botteman M, Snider J, Locke F
J Med Econ
. 2021 Mar;
24(1):458-468.
PMID: 33691581
Aims: To assess from a US payer perspective the cost-effectiveness of the chimeric antigen receptor T (CAR T)-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) to treat relapsed or refractory...
3.
Lindstrom R, Berdahl J, Donnenfeld E, Thompson V, Kratochvil D, Wong C, et al.
J Med Econ
. 2020 Nov;
24(1):410-420.
PMID: 33210975
Aims: To assess the cost-effectiveness of corneal collagen cross-linking (CXL) versus no CXL for keratoconus in the United States (US). Methods: A discrete-event microsimulation was developed to assess the cost-effectiveness...
4.
Aly A, Johnson C, Doleh Y, Shenolikar R, Botteman M, Hussain A
J Comp Eff Res
. 2020 Sep;
9(13):945-957.
PMID: 32964721
To understand physician visit patterns among patients with stage IV (including nonmetastatic [M0] and metastatic [M1] disease) urothelial carcinoma (UC) and understand factors associated with a timely referral to a...
5.
Aly A, Singh P, Korytowsky B, Ling Y, Kale H, Dastani H, et al.
Neurooncol Pract
. 2020 Jul;
7(2):164-175.
PMID: 32626585
Background: Glioblastoma (GBM) is associated with poor prognosis, large morbidity burden, and limited treatment options. This analysis evaluated real-world treatment patterns, overall survival, resource use, and costs among Medicare patients...
6.
Gonzalez-Duarte A, Conceicao I, Amass L, Botteman M, Carter J, Stewart M
Neurol Ther
. 2020 Apr;
9(1):135-149.
PMID: 32232748
Introduction: Hereditary (variant) transthyretin amyloidosis (ATTRv) with polyneuropathy (ATTR-PN) is a rare genetic disorder that causes progressive autonomic and sensorimotor neuropathy, severe disability, and death within 10 years of onset....
7.
Macarulla T, Hendifar A, Li C, Reni M, Riess H, Tempero M, et al.
Pancreas
. 2020 Mar;
49(3):393-407.
PMID: 32132518
Objectives: Pancreatic resection is associated with postoperative morbidity and reduced quality of life (QoL). A systematic literature review was conducted to understand the patient-reported outcome measure (PROM) landscape in early-stage...
8.
Aly A, Johnson C, Yang S, Botteman M, Rao S, Hussain A
J Med Econ
. 2019 Mar;
22(7):662-670.
PMID: 30836812
Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT), but invariably progress, requiring additional LOTs and healthcare resource use...
9.
Waddington-Cruz M, Schmidt H, Botteman M, Carter J, Stewart M, Hopps M, et al.
Orphanet J Rare Dis
. 2019 Feb;
14(1):34.
PMID: 30736835
We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from...
10.
Aly A, Shah R, Hill K, Botteman M
Future Oncol
. 2019 Feb;
15(9):1007-1020.
PMID: 30717602
Aim: This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients. Materials & Methods: Patients (≥66 years) with metastatic triple-negative breast cancer...